Threshold Pharmaceuticals, Inc (THLD): Opiniones

Jo, y yo que los jueves ando liada. Me voy a perder toda la testosterona de hoy. Cuidadme bien a la churri.

Pero, ¿Esa información tan solo está al alcance de unos poquitos?

El otro día en el foro de Farmas @Framus precisamente comentaba que no había dedo que aguantara semejantes subidas y alguien (¿quién fue?) replicó que había estudios que dicen que sí,y que ese dedo es femenino. Quería haber contestado y pedido los datos, pero se me pasó el tiempo... Me gustaría recuperar el debate.

En fin, que creo en la estadística y conozco bien esa capacidad femenina. Sin embargo, dudo que ese montaje se aguante para una cartera biotech; en caso de llevar una sola farma ya sería otro cantar.

Me explico. Dada la volatilidad de las farmas, si sigues ese procedimientos de convencimiento para todas te vas a ir dando una hostia tras otra, por lo que el cuerpo femenino te pedirá ir reequilibrando la pasta con el resto de posiciones y aunque acabes llevándote el premio final de una, habrás ido palmando en otras por el camino.

Yo también creo en THLD, pero hay que estar atenta a los datos, que al final no tenemos ni un producto, solo humo.

A que te refieres?
acceder a la info o "procesarla"

El valor clave es EPS : Earnings Per Share
Es en lo primero que me fijo.

Me refiero a esto que comentabas:

"Veremos que sucede cuando se libere que tiene un +400% mas de cash al termino de 2012 con respecto a lo que tenia en 2011."

Te preguntaba que si es una información que pueda subir el valor por ser desconocida entre la mayoría de los inversores o lo contrario.

S2

Llevas toda la razón...evidentemente aguanto porque es la única farma que tengo, estoy en ella por casualidad y "creo" que tengo motivos para mantener la fe en ella.

Hay muy poco de ludopatía en este cuerpo :), no me meto en otra ni de casualidd, eso si...le estoy cogiendo el gusto a ver los toros desde la barrera.

(Me quedo con tu última frase!!!!!, porque además hace muy poco hablando con un amigo que trabaja en Roche me recordó que el 85% de los medicamentos en FASE 3 no llegan a ver la luz)

pienso que todos aquellos que tengan interes y hayan leido sobre THLD estaran al tanto del tema cash, milestones y alianza con Merck.

Los que no sepan de THLD e inviertan en Biotech, con todo el ruido que ha hecho en 2012 ... Instituciones desde luego no, retail si cabe ...

http://investor.thresholdpharm.com/releasedetail.cfm?ReleaseID=746204

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/07/13 -- Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2012 and provided a clinical outlook related to the development of TH-302, the company's lead investigational hypoxia-targeted drug currently in pivotal Phase 3 clinical studies for both soft tissue sarcoma and pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2012 was $2.0 million and $5.9 million, respectively. Net income for the fourth quarter ended December 31, 2012 was $28.4 million, which included the operating loss of $6.0 million and non-cash income of $34.4 million related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2012 was $71.1 million, which included the operating loss of $20.0 million and non-cash expense of $51.2 million related to changes in the fair value of the Company's outstanding and exercised warrants. As of December 31, 2012, Threshold had $70.8 million in cash, cash equivalents and marketable securities, with no debt outstanding. Subsequent to December 31, 2012, Threshold received an additional $42.5 million in milestone payments under its agreement with Merck KGaA, Darmstadt, Germany.

"2012 was a transformative year for Threshold during which we entered a strategic partnership with Merck KGaA and made significant advances in the clinical development of TH-302," said Barry Selick, Ph.D., Chief Executive Officer of Threshold. "We started early 2013 with more than $100 million in cash and investments and with TH-302 in eight actively recruiting clinical trials, including two pivotal Phase 3 studies. We are pleased with progress in the Phase 3 trial of TH-302 in patients with soft tissue sarcoma and look forward to reporting data from our earlier-stage trials by the end of the year."

Fourth Quarter and Year End 2012 Financial and Operational Results

The net income for the fourth quarter of 2012 was $28.4 million compared to a net loss of $5.3 million for the fourth quarter of 2011. Included in the net income for the fourth quarter of 2012 was non-cash income of $34.4 million compared to non-cash income of $2.8 million in the fourth quarter of 2011. The net loss for 2012 was $71.1 million compared to a net loss of $25.7 million in 2011. Included in the net loss for 2012 was non-cash expense of $51.2 million compared to non-cash income of $4.4 million in 2011. The non-cash income or expense is related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense).

Revenue for the fourth quarter and year ended December 31, 2012 was $2.0 million and $5.9 million, respectively, compared to $0.1 million for the same periods in 2011. Revenue for 2012 was related to a $25 million upfront payment and $42.5 million in milestone payments earned from our global license and co-development agreement for TH-302 with Merck KGaA. Subsequent to December 31, 2012, Threshold earned an additional $30 million milestone payment. The revenue from the upfront payment and milestone payments earned under the agreement is being amortized over the relevant performance period, rather than being immediately recognized when the upfront payment and milestone are earned or received. To date, the Company has received $97.5 million in upfront and milestone payments. Threshold could also receive an additional $12.5 million in a potential milestone payment in 2013. Revenue for 2011 was related to a pre-existing license agreement with Eleison Pharmaceuticals, Inc.

Research and development expenses were $6.2 million for the fourth quarter of 2012, compared to $6.7 million for the fourth quarter of 2011. The $0.5 million net decrease in research and development expenses are primarily related to the $3.0 million reimbursement credit obtained as part of Merck KGaA's 70% share of total TH-302 development funding under the Merck KGaA collaboration, partially offset by an increase of $2.5 million in clinical development and employee related expenses. Research and development expenses were $18.8 million for 2012, compared to $24.4 million in 2011. The $5.6 million net decrease in research and development expenses are primarily related to the $12.6 million reimbursement credit obtained as part of Merck KGaA's 70% share of total TH-302 development funding under the Merck KGaA collaboration, partially offset by an increase of $3.6 million in clinical development expenses and $3.4 million in employee related expenses.

General and administrative expenses were $1.9 million for the fourth quarter of 2012 versus $1.4 million for the fourth quarter of 2011. General and administrative expenses were $7.1 million for 2012 versus $5.7 million in 2011. The increase in general and administrative expenses was due to an increase in employee related expenses and consulting expenses. Non-cash stock-based compensation expense included in operating expenses was $0.9 million for the fourth quarter of 2012 versus $0.3 million for the fourth quarter of 2011. Non-cash stock-based compensation expense included in operating expenses was $3.0 million for 2012 versus $1.0 million in 2011. The increase in stock-based compensation expense is due to the amortization of a greater number of options with a higher fair value.

As of December 31, 2012, and 2011 Threshold had $70.8 million and $20.3 million in cash, cash equivalents and marketable securities. The net increase in cash, cash equivalents and marketable securities during 2012 is primarily due to the $55 million in upfront and milestone payments received from our collaboration with Merck KGaA, $12.3 million from equity issuances related to our at the market sales offering and $8.8 million from the exercise of warrants.